SCHEMBL1460040

SCHEMBL1460040

Cc1cc(Cl)ccc1-c1ccc2[nH]c(-c3c(F)cccc3F)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 0.45
PPARG P37231 3/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 4/20 0.45
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
CYP19A1 P11511 1/20 0.45
ORAI1 Q96D31 2/20 0.42
CYP2C9 P11712 2/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464225 0.89 ALDH1A1 (0.46) FFAR1PPARGMEN1KMT2AALDH1A1
SCHEMBL1460100 0.88 CYP1A1 (0.49) FFAR1PPARGMEN1KMT2AALDH1A1
SCHEMBL1460846 0.84 HPN (0.39) FFAR1PPARGMEN1KMT2AALDH1A1
SCHEMBL1458818 0.83 KDM4E (0.49) FFAR1MEN1KMT2AALDH1A1NPC1
SCHEMBL1459615 0.82 CYP19A1 (0.48) CYP19A1ORAI1CYP1A1
SCHEMBL1459748 0.81 FFAR1 (0.42) FFAR1PPARGCYP1A1HPN
SCHEMBL1458789 0.81 TRPA1 (0.41) FFAR1MEN1KMT2ANPC1RAB9A
SCHEMBL1460252 0.80 ORAI1 (0.46) FFAR1CYP19A1ORAI1CYP2C9CYP1A1
SCHEMBL1459974 0.79 ROCK2 (0.42) FFAR1PPARGMEN1KMT2AALDH1A1
SCHEMBL1459760 0.78 IL2 (0.40) ORAI1CYP2C9CYP1A1PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP claimed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO claimed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US claimed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E FFAR1 318/4885PPARG 2826/4885MEN1 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.